How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

A Phase 2, Multicenter, Single-Arm Study to Evaluate the Safety and Dystrophin Expression After Fordadistrogene Movaparvovec (PF-06939926) Administration in Male Participants With Early Stage Duchenne Muscular Dystrophy

calendar_today October 30, 2026 person reddym75 domain pfizer

A Phase 2, Multicenter, Single-Arm Study to Evaluate the Safety and Dystrophin Expression After Fordadistrogene Movaparvovec (PF-06939926) Administration in Male Participants With Early Stage Duchenne Muscular Dystrophy reddym75 Fri, 10/30/2026 - 06:30 PF-06939926 Fordadistrogene Movaparvovec PHASE II Mon, 08/08/2022 - 12:00 Fri, 10/03/2025 - 12:00 NCT05429372 C3391008 Public Disclosure Synopsis .pdf (123.37 KB) N https://clinicaltrials.gov/study/NCT05429372 C3391008

open_in_new Read original post